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Abstract: The gram-negative bacterial pathogen Pseudomonas aeruginosa represents a prominent
clinical concern. Due to the observed high levels of antibiotic resistance, copious biofilm formation,
and wide array of virulence factors produced by these bacteria, new treatment technologies are
required. Here, we present the development of a series of P. aeruginosa LecA-targeted polymeric
nanoparticles and demonstrate the anti-adhesion and biofilm inhibitory properties of these constructs.
Keywords: biofilm; inhibition; antivirulence; lectin; Pseudomonas aeruginosa; nanoparticle
1. Introduction
The ongoing increase of antibiotic resistance represents a significant challenge to modern
medicine [1–3]. Due to the widespread use of antibiotics in clinical and agricultural settings and the
limited number of novel antibiotics being advanced into the market, the development of new treatment
options for bacterial infection is of paramount importance.
Pseudomonas aeruginosa represents one of the most significant gram-negative opportunistic
pathogens involved in hospital-acquired infections. A report from the CDC-NNIS (National Nosocomial
Infections Surveillance, US Dept. of Health and Human Services) identifies P. aeruginosa as the second
leading cause of pneumonia, the third leading cause of urinary tract infection, and the eighth most
frequently isolated pathogen from the bloodstream [1–7]. Further, P. aeruginosa often causes lethal
infections in cystic fibrosis and immunocompromised patients, for whom the formation of bacterial
biofilms plays a central role in infection and resistance [8,9]. Given the rapidly increasing incidence
of P. aeruginosa in the clinic coupled with the high levels of antibiotic resistance and production of
copious biofilms often found with this pathogen, the development of novel treatment strategies is
imperative [10–12].
In P. aeruginosa, biofilm formation is regulated by a cell-cell communication mechanism known as
quorum sensing, which is mediated by bacterial cell-surface lectins involved in cellular adhesion [13,14].
Specifically, the galactose-binding lectin LecA (PA-IL) and the fucose-binding lectin LecB (PA-IIL)
have prominent roles in bacterial virulence, cellular adhesion, tissue colonization, and/or invasion and
biofilm formation [15–17]. Several recent reports have evaluated approaches to inhibit the virulence
and/or biofilm formation in P. aeruginosa through inhibition of quorum sensing or lectin binding.
Notable about these anti-virulence approaches is the potential they possess for species-selectivity by
targeting the inhibition of cellular processes in a manner that uniquely inhibits the virulence and/or
infectivity of P. aeruginosa. Accordingly, treatments developed for these P. aeruginosa-specific targets are
Pathogens 2019, 8, 55; doi:10.3390/pathogens8020055 www.mdpi.com/journal/pathogens
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anticipated to have a lower impact on the beneficial commensal bacterial population and may possibly
exhibit reduced pressure for the development of antibiotic resistance.
Prior studies developing inhibitors of P. aeruginosa LecA have described mono-valent and
multi-valent inhibitors of this lectin and have characterized the positive effect on inhibitor avidity
through multivalency [12,17]. We rationalized that we might achieve similar high binding avidity
for LecA using a polymeric nanoparticle with multiple copies of a LecA ligand on the surface
of the particle. Further, we recognized that unlike dendrimeric or small molecule inhibitors
of LecA, the surface-modified polymeric nanoparticles that we aimed to prepare would be capable of
encapsulating a fluorescent or drug molecule within their lipophilic core, potentially enabling future
applications in targeted antibiotic drug delivery or fluorescent labeling for diagnostic applications.
Here we report our findings on the development and anti-biofilm properties of a series of LecA-targeted
polymeric nanoparticles.
2. Results
2.1. Synthesis of Galactose-Modified Di-block Co-polymer
The D-galactose-modified di-block co-polymer required for nanoparticle assembly (5) was
prepared from β-D-galactose pentaacetate in six steps (Scheme 1). In short, β-D-galactose pentaacetate
(1) was coupled to benzyl 4-hydroxybenzoate (2) to provide ester 3. Removal of the benzyl protecting
group by hydrogenolysis provided carboxylic acid 4, which was coupled to 6.6 kD amine terminated
di-block co-polymer [18]. Removal of the acetate protecting groups on the sugar preceded purification
of the sugar-modified polymer 1 by dialysis using a 5 kD molecular weight cutoff (MWCO) membrane.
The resulting dialyzed D-galactose-modified polymer (5) was concentrated by lypohilization and the
resulting white powder was characterized by NMR, IR, and MALDI-MS. Having prepared the requisite
galactose-modified di-block copolymer 5, we proceeded with the assembly of polymeric nanoparticles.
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Scheme 1. Synthesis of modified di-block co-polymer for nanoparticle assembly. Abbreviations: DCM,
dichloromethane; ACN, acetonitrile; MWCO, molecular weight cutoff.
2.2. Nanoparticle Preparation
Nanoparticles were prepared by flash nanoprecipitation using established methods [18,19] with
varying ratios of the modified D-galactose polymer and unmodified di-block co-polymer to provide
100%-, 50%-, and 25%-surface-modified nanoparticles using the parameters described in Table 1.
All nanoparticles were prepared using racemic α-tocopherol (vitamin E) as an inert core stabilizer.
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Table 1. Summary of polymeric nanoparticle (NP) prepared with varying levels of surface modification.
Formulation














0% PS-b-PEG-Gal 0.00 PS-b-PEG 0.40 VitE 0.40 88.83 ± 4.64 0.0327
25% Gal-NP PS-b-PEG-Gal 0.10 PS-b-PEG 0.30 VitE 0.40 73.78 ± 2.23 0.0132
50% Gal-NP PS-b-PEG-Gal 0.20 PS-b-PEG 0.20 VitE 0.40 74.74 ± 2.26 0.0083
100% Gal-NP PS-b-PEG-Gal 0.40 PS-b-PEG 0.00 VitE 0.40 81.47 ± 12.75 0.2693
1 Data represent the mean with error described as the standard error of means of at least three independent
preparations of the particles, each with three instrumental replicates. 2 Polydispersity Index (PDI) = (standard
deviation/mean diameter)ˆ2. Abbreviations: VitE, vitamin E (α-tocopherol).
All D-galactose nanoparticle (Gal-NP) suspensions were prepared as 0.02 mg/mL solutions in
water and characterized in terms of particle diameters (Figure 1) and polydispersity indexes (PDI).
The particles prepared are described in this manuscript based on the relative concentration of
surface-modified D-galactose to enable direct comparison of the effect of the prepared nanoparticles
on lectin binding and biofilm inhibition to free D-galactose, used as a control. Having prepared a
series of galactose-modified polymeric nanoparticles, we conducted an evaluation of the lectin binding
properties of the prepared particles.
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Figure 1. (A) Schematic showing assembly of D-galactose surface-modified polymeric nanoparticles.
(B) Particl size distribution of prepared p lymeric nanoparticles. Each data poi t re resents the
average particle diameter of a independent for ulatio . (C) Histogram of particle size distribution
for all nanoparticles prepared in this study.
2.3. Inhibition of LecA-Mediated Hemagglutination
The binding affinity of the modified nanoparticles for the P. aeruginosa lectin LecA was evaluated
using a hemagglutination assay [20]. Briefly, this assay measures the inhibition of LecA-induced
hemagglutination of rabbit erythrocytes by comparison with D-galactose as a control. The exceptional
effect of ligand multivalency was noted with the 100%- and 50%-modified NP samples, which were
evaluated based on the concentration of galactose on the surface of the nanoparticles (Table 2).
The strongest effect was observed with the 50%-modified Gal-NP, showing a 992-fold increase
in relative potency compared with free galactose. The 100%-modified Gal-NP samples inhibited
hemagglutinat on when modified i concentrations above 6.31µM of galactose, representing a
495-fold increase i p l tive to fr e galactose. The 25%-modified NP showed o inhibition of
hemagglutination up to the highest surface concentration of D-galactose evaluated (2.36 µM). A control
100%-mannose-modified polymeric NP (37.9 µM mannose) showed no inhibition of hemagglutination,
supporting the hypothesis that the inhibition of LecA is mediated by specific interactions between the
lectin and the nanoparticle surface only with galactose modification.
The high potency of the particles in this assay is consistent with previous reports of high avidity
LecA binding using galactose modified dendrimers [12,20]. It is noted that the % modification of
the particle leads to maximal inhibition with the 50%-sugar-modified particles. Particles with lower
galactose modification (25%-modified) showed no inhibition of hemagglutination at the highest
concentrations tested ([galactose] = 2.36 µM) and those with higher modification (100%-modified)
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had a two-fold higher MIC. It is possible that a sugar concentration greater than 2.36 µM on the
nanoparticles is required for high avidity; however, higher sugar concentrations as would be present
in the 100%-modified nanoparticles result in the steric inhibition of lectin binding.
Table 2. Inhibition of P. aeruginosa LecA-induced hemagglutination.
Entry Formulation Hemagglutination Assay MIC (uM) 1 Relative Potency 4
1 D-galactose 3125.0 1.0
2 100%-Modified D-galactose-NP 6.31 495.2
3 50%-Modified D-galactose-NP 3.15 992.1
4 25%-Modified D-galactose-NP none 2 -
5 100%-Modified mannose-NP none 3 -
1 MIC = minimal inhibitory concentration for the hemagglutination assay following two-fold serial dilutions
of tested compounds; the MIC corresponds to the highest dilution resulting in the inhibition of LecA-induced
hemagglutination based on the relative sugar concentration. 2 No inhibition of hemagglutination up to highest
concentration evaluated (galactose concentration of 2.36 µM). 3 No inhibition of hemagglutination up to highest
concentration evaluated (maltose concentration of 37.9 µM). 4 Relative potency based on concentration of galactose
= (MIC(D-galactose)/MIC(ligand)).
2.4. Inhibition of P. aeruginosa PAO1 Biofilm Formation
Having identified that our 100%- and 50%-D-galactose-modified polymeric nanoparticles are
effective at inhibiting LecA-induced hemagglutination, we evaluated their effect on bacterial biofilm
formation using the well-established crystal violet assay [21,22]. Briefly, P. aeruginosa strain PAO1
was inoculated in 96-well plates in the presence of varying concentrations of Gal-NP, controls, and/or
free D-galactose. Biofilm formation was evaluated after 24 h by removing non-adherent bacteria,
crystal violet staining of the adherent cells, and determination of absorbance at 550nm. In this assay,
we observed a potent dose-dependent inhibition of biofilm formation with our surface-modified
Gal-NP samples (Figure 2). Inhibition of biofilm formation was noted at D-galactose concentrations
above 12.6 µM in the 100%-surface-modified nanoparticle samples and at concentrations above 6.3 µM
in the 50%-surface-modified series. Again, the significance of ligand valency is evident, as free
D-galactose, even at 32,000 µM, showed no inhibition of biofilm formation in this assay.Pathogens 2019, 8, 55 5 of 13 
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2.5. Evaluation of Growth Inhibition
To confirm that the potent biofilm inhibitory activity observed was not due to growth inhibition
by the nanoparticle samples evaluated, we collected full growth curve data for PAO1 by monitoring
OD600 (Figure 3). We were surprised to find that the highest concentration of 100%- and 50%-modified
nanoparticles (correlating to D-galactose concentrations of 75.8 µM and 37.8 µM, respectively) did
potently inhibit bacterial growth. Despite this, no significant inhibition of growth was noted at any
of the nanoparticle concentrations evaluated in our biofilm inhibition assay. The absence of growth
inhibition supports the hypothesis that that nanoparticle-LecA binding interactions inhibit bacterial
biofilm formation via an antivirulence (non-antibiotic) mechanism.
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Figure 3. Evaluation of P. aeruginosa PAO1 growth by monitoring OD600 with
100%-D-galactose-surface-modified nanoparticles (A) and 50%-D-galactose-surface-modified
nanoparticles (B). No significant growth inhibition is observed with 100%-modified Gal-NP at
concentrations below 37.9 µM or with 50%-modified Gal-NP at concentrations below 18.9 µM. Growth
inhibition was noted at concentrations two-fold higher than those employed in the biofilm inhibition
assays (100% Gal-NP at 75.8 µM and 50% Gal-NP at 37.8 µM). Error bars represent standard deviation
of triplicate analysis.
2.6. Evaluation of Biofilm Inhibition and Morphology
We s bsequently eval ated the i hibition f biofilm formation in the hyper-virulent isolate
of P. aer gin sa PA14 by fluorescent confocal micr scopy. Briefly, 24-h biofil s were prepared by
inoculation of PA14-GFP [23] i to Luria broth (LB) contai ing the appropriate treatments or controls.
The resulting biofilm was then evaluated by fluorescent confocal microscopy. In this experiment,
we observed clear changes in the overall biomass and average biofilm thickness of the Gal-NP-treated
samples, consistent with our observations in the crystal violet assay. Additionally, in this experiment,
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we captured distinct changes in the morphology of the biofilm that are evident at sub-inhibitory
concentrations. These observations further support the inhibition of cellular adhesion by D-galactose
surface modified nanoparticles.
Within the 100%- and 50%-surface-modified samples of nanoparticles we observed the inhibition
of biofilm formation based on evaluation of biofilm biomass and average biofilm thickness at
concentrations above ~19.5 µM; however, effects on biofilm morphology were apparent at even
lower concentrations (Figure 4). The slightly higher concentrations required to inhibit biofilm
formation in the hypervirulent PA14 strain, compared with our crystal violet assay with PAO1,
are consistent with previous studies of this bacteria [24,25]. In this assay, we observed no inhibition of
biofilm formation by free D-galactose, even at concentrations of 48,000 µM (Figures 4 and 5). Visual
inspection of the images collected (Figure 4 and Supporting Information) show that with increasing
concentration of D-galactose-modified nanoparticles the biofilm begins to display increasing numbers
of spaces within the biofilm structure (Figure 4, panel A vs. B vs. D). This effect is consistent with the
anticipated inhibition of cellular adhesion achieved by inhibiting the activity of LecA in the presence
of Gal-modified nanoparticles.
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Figure 4. Fluorescent confocal microscopy evaluation of P. aeruginosa PA-14 biofilms. Samples
treated with Gal-NP show inhibition of biofilm formation. The biofilm morphology at sub-inhibitory
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Gal-NP, which increase with higher concentrations. For additional images see Supporting Information.
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Quantification of the biomass and average biofilm thickness of the confocal images using the
program Comstat2 shows dose-dependent inhibition of biofilm formation (Figure 5a,b). Most striking
is the quantification of biofilm surface area as a function of volume. This calculation nominally provides
a measure of the quantity/size of spaces within the biofilm structure. Consistent with the hypothesis
that Gal-NP inhibit cellular adhesion without inhibiting growth/viability, we observe a dose-dependent
increase in the biofilm surface area/volume (Figure 5c).
3. Discussion
Recently, significant interest has been directed at the development of antivirulence strategies
to combat infectious diseases. As these approaches do not directly impact viability or growth,
a reduced selective pressure for resistance is anticipated. For the inhibition of biofilm formation,
many antivirulence agents being developed focus on the inhibition of the quorum-sensing signaling
pathways [14,24,26] or inhibition of bacterial adhesion [20,27,28]. Bacterial lectins are implicated in
key roles in bacterial adhesion and biofilm formation, including the lectins LecA and LecB, which
play a prominent role in P. aeruginosa. Here we report the development of the first LecA-targeted
surface-modified polymeric nanoparticle. The particles prepared showed high avidity for LecA in the
inhibition of hemagglutination, consistent with a beneficial effect of multivalent display of the lectin
ligand on the particle surface. We observed greater than 100-fold enhancement in potency, compared
with free D-galactose in the assay with 100%- and 50%-surface modified D-galactose nanoparticles.
Further, we demonstrated potent inhibition of P. aeruginosa biofilm formation in the presence of these
surface-modified nanoparticles, demonstrating the anti-virulence potential of these novel inhibitors of
the P. aeruginosa lectin LecA.
Previous studies have shown that LecA is cytotoxic [29] and has an important role in cellular
adhesion and lung infection [17]. LecA is a homotetramer and displays specificity for galactose. Due to
the high affinity of LecA for galactose, numerous multivalent and dendrimer structures have been
developed as inhibitors of this protein [12,20,27,28]. The significant increase in LecA binding potency
noted in these dendrimeric constructs was captured in the polymeric nanoparticles in this study, which
were found to be potent inhibitors of LecA-induced hemagglutination and bacterial biofilm formation.
Notably, the assembly of nanoparticles as highly multivalent scaffolds for lectin binding avoids
many of the synthetic challenges of dendrimer synthesis [30,31]. Accordingly, we anticipate that
the application of polymeric nanoparticles to achieve the high lectin-binding potency observed with
dendrimers, as demonstrated here, will serve as a powerful and useful complimentary approach for
the inhibition of bacterial lectins and other cell-surface receptors. Self-assembly of sugar-modified
di-block co-polymers using flash nanoprecipitation [19] further enables ready introduction of multiple
different ligands to enable targeting multiple biological targets with a single nanoparticle construct,
further enhancing biological activity.
Polymeric nanoparticles have been extensively studied in several medical technologies, especially
in the area of drug delivery [11,32–37]. The advantages of improved pharmacokinetics and therapeutic
properties, including mucus penetration [38], continue to stimulate interest in the field. As demonstrated
here, surface modification of the nanoparticle enables targeting of the constructs to the bacterial
pathogens of interest, potentially enabling species-specific delivery of drugs, diagnostic reagents,
or other small molecules.
4. Conclusions
In conclusion, polymeric nanoparticles synthetically modified to provide surface display of
conjugated D-galactose bind to the P. aeruginosa lectin LecA with high potency. The benefit of high
ligand valency to achieve high avidity lectin binding is efficiently realized in these constructs. Several
of the polymeric nanoparticles were found to inhibit biofilm formation in a manner consistent with
an antivirulence (anti-adhesion) mechanism of action, providing a new and powerful technology for
species-specific inhibition of bacterial virulence.
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5. Methods and Materials
5.1. General Experimental
Unless otherwise noted, all reactions were performed in flame-dried glassware under an
atmosphere of nitrogen or argon using dried reagents and solvents. All chemicals were purchased
from commercial vendors and used without further purification. Anhydrous solvents were purchased
from commercial vendors.
Flash chromatography was performed using standard grade silica gel 60 230-400 mesh from
SORBENT Technologies or using a Biotage Flash Purification system equipped with Biotage SNAP
columns. All purifications were performed using gradients of mixtures of ethyl acetate and hexanes.
Analytical thin-layer chromatography was carried out using Silica G TLC plates, 200 µm with UV254
fluorescent indicator (SORBENT Technologies), and visualization was performed by staining and/or
absorbance of UV light.
NMR spectra for small molecules were recorded using a Varian Mercury Plus spectrometer
(400 MHz for 1H-NMR; 101 MHz for 13C-NMR). Chemical shifts are reported in parts per million (ppm)
and were calibrated according to residual protonated solvent. Mass spectroscopy data was collected
using an Agilent 1100-Series LC/MSD Trap LC-MS or a Micromass Quattromicro with a Waters 2795
Separations Module LC-MS with acetonitrile containing 0.1% formic acid as the mobile phase in
positive ionization mode. Small molecule purity was determined on an Agilent 1100 series equipped
with a Phenomenex Kinetex 2.6 µm C18-UPLC column using a gradient of water to acetonitrile with
0.1% TFA.
All final compounds were evaluated to be of greater than 90% purity by analysis of 1H-NMR,
13C-NMR, and/or analytical HPLC.
5.2. Synthesis of D-Galactose-Modified Polymers
(2S,3R,4S,5S,6R)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate, 2.
D-galactose (5.00 g, 27.75 mmol) was dissolved in acetic acid (185 mL, 0.15 M) at room
temperature. Acetyl bromide (16.40 mL, 222.02 mml) was added and the mixture was allowed to
stir for 1 h. The resulting solution was washed with toluene (2x, 40 mL), dried over sodium sulfate,
and concentrated to dryness. The residue was purified by flash chromatography using a gradient of
hexanes to EtOAc to provide (2S,3R,4S,5S,6R)-6-(acetoxymethyl) tetrahydro-2H-pyran-2,3,4,5-tetrayl
tetraacetate. Characterization data was consistent with a commercial sample of this compound.
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-((benzyloxy)carbonyl)phenoxy)tetrahydro-2H-pyran-
3,4,5-triyl triacetate, 4. (2S,3R,4S,5S,6R)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl
tetraacetate, 2 (2 g, 5.12 mmol) was dissolved in dichloromethane (10 mL, 0.5 M) at room temperature.
Hydrobromic acid (33% in AcOH, 1.485 mL) and acetic acid (3.015 mL, 1.14 M) were added and the
mixture was allowed to stir. After 30 min, the solution was diluted with 50 mL of DCM, washed
with sodium bicarbonate, dried with sodium sulfate, and concentrated to dryness. The residue (2 g)
was re-dissolved in DCM (30 mL, 1.5 M) and treated with benzyl-4-hydroxybenzoate, 3 (2.34 g,
10.03 mmol), tetrabutylammonium hydrogensulfate (1.74 mg, 5.12 mmol), and 0.5 M sodium hydroxide
(10 mL, 0.5 M). The biphasic mixture was allowed to stir overnight at room temperature, was diluted
with DCM and acidified with 1M HCl, extracted with DCM (3 x 50mL), dried over Na2SO4, and
concentrated to dryness. The residue was purified by flash chromatography using a gradient of
hexanes to EtOAc to provide (2R,3S,4S,5R,6S)-2- (acetoxymethyl)-6-(4-((benzyloxy)carbonyl)phenoxy)
tetrahydro-2H-pyran-3,4,5-triyl triacetate, 4 (1.006 g, 1.848 mmol, 40.76%). 1H NMR (400 MHz, CDCl3)
δ1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.9 Hz, 2H), 7.40–7.22 (m, 5H), 6.95 (d, J = 8.4 Hz, 2H),
5.48–5.37 (m, 2H), 5.27 (s, 2H), 5.11–5.01 (m, 2H), 4.20–3.95 (m, 3H), 2.11 (s, 3H), 1.98 (s, 6H), 1.94 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 170.44, 170.30, 170.19, 169.44, 165.88, 160.46, 136.19, 131.84, 128.72,
128.37, 128.25, 125.14, 116.30, 98.93, 71.39, 70.84, 68.59, 66.93, 66.76, 66.76, 61.50, 20.82, 20.79, 20.76,
20.69, 0.12. ESI-MS: predicted for C28H31O12 [M + H]+ 559.544, observed, 559.569.
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4-(((2S,3R,4S,5S,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic
acid, 5. (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-((benzyloxy)carbonyl)phenoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate, 4 (0.719 g, 1.320 mmol) was dissolved in methanol (6.6 mL, 0.2 M)
and palladium on carbon (10%, 16 mg, 0.1 mmol) was added to the reaction flask at room
temperature. Hydrogen was added via balloon and the reaction was stirred overnight at
room temperature. The residue was separated by vacuum filtration washing with methanol
to yield 4-(((2S,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)
methoxy)benzoic acid, 5 (571.2 mg, 1.219 mmol, 61.85%). 1H NMR (400 MHz, CDCl3) δ 8.05 (d,
J = 8.3 Hz, 2H), 7.03 (d, J = 8.3 Hz, 2H), 5.57–5.43 (m, 2H), 5.20–5.07 (d, J = 51.1 Hz, 2H), 4.28–4.06
(d, J = 84.7 Hz, 3H), 2.19 (s, 3H), 2.06 (s, 6H), 2.02 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 171.98,
171.91, 171.38, 171.22, 161.55, 132.97, 132.72, 117.02, 115.98, 99.36, 72.27, 72.16, 70.02, 68.67, 62.60, 49.00,
24.74, 20.69, 20.60, 20.54, 20.50, 20.49, 13.93. ESI-MS: predicted for C21H24O12Na [M + Na]+ 491.401,
observed, 491.477.
PS-b-PEG-Galactose, 1. To a room temperature solution of
4-(((2S,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)
methoxy)benzoic acid, 5 (20.5 mg, 0.068 mmol) in DMF (340uL) was added
(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (30.1 mg, 0.068
mmol) and the mixture was allowed to stir for 5 min before the addition of PS-b-PEG-NH2 (150 mg,
0.023 mmol, 6.6 kD, prepared from PS-b-PEG-OH as previously described [18]). The resulting solution
was stirred at room temperature overnight. The reaction was quenched by the addition of water (1 mL)
and EtOH (1 mL), and loaded into a 3.5 kD MWCO dialysis cassette (PierceTM Slide-A-LyzerTM G2,
Thermo Scientific). The mixture was dialyzed into water for 12 h, at which time the dialysis cassette
was transferred to a fresh solution of water and further dialyzed for an additional 12 h. After dialysis,
the retained solution was lyopholyzed to provide PS-b-PEG-galactose, 1, as a white powder (153.6 mg,
quantitative). The product was characterized by MALDI-MS (Bruker MicroFlex LFR MALDI-TOF) in
positive linear detection mode using a matrix of dithranol:polymer of 1:1 evaporated from DCM onto
a polished steel target. Collected spectra were analyzed with the Flex Analysis software (Bruker);
the unmodified PS-b-PEG-NH2 was evaluated in the same manner as a standard. The observed m/z
for PS-b-PEG-NH2 was 6212.07, and the observed m/z for PS-b-PEG-galactose was 6501.40, consistent
with complete polymer modification (anticipated ∆ m/z for polymer modification = 282.24).
5.3. Nanoparticle Assembly
Nanoparticles with defined levels of surface modification were prepared through flash
nanoprecipitation (FNP) as previously described [18,19,39]. Briefly, PS, vitamin E (VitE), PS-b-PEG,
PS-b-PEG-galactose, and/or PS-b-PEG-mannose were dissolved at defined compositions in THF and
rapidly micromixed with an equivalent volume of water within a confined impingement jet mixer,
manufactured using HDPE (The Inventors Shop, Cinnaminson, NJ, USA), following the specifications
provided [40], and diluted tenfold in a water collection bath. Particles with 0–100%-surface-modification
of galactose or mannose were prepared using defined combinations of PS-b-PEG/PS-b-PEG-galactose or
PS-b-PEG-mannose. Vitamin E was used as the core bulking material in all NP formulations. Particle
sizes were assessed with dynamic light scattering analysis (90Plus Particle Size Analyzer, Brookhaven
Instruments Corporation). Size distributions were determined with backscattering measurements
from 658-nm illumination and displayed as intensity-weighted distributions; ‘particle diameter’ is the
hydrodynamic diameter as calculated by DLS based on the Stokes Einstein equation using instrumental
software. The composition of particles formed and particle size characterization data is provided in
Table 1.
5.4. Hemagglutination Assay
The LecA-induced hemagglutination assay was performed as reported with modifications [20].
LecA (PA-IL) was purchased from Sigma-Aldrich and used as received. Rabbit red blood cells
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(Innovative Research) at 100% were washed three times with 150 mM NaCl solution then diluted to
5% with NaCl (150 nM) solution. A hemocytometer was used to count the number of red blood cells
that were in red blood cell solution and solutions were normalized to 2.94 × 1014 cells/mL. To find
the minimal full hemagglutination inhibition concentration for LecA, a serial dilution was performed
from a stock solution of 1 mg/mL LecA. Briefly, LecA (15 µL) was diluted into Tris buffer (Tris 20 µM,
NaCl 100 mM, CaCl2 100 µM, pH = 7.5, 35 µL) in 96-well microtiter V-bottom plates and was subjected
to a two-fold serial dilution. Normalized 5% blood solution (10 µL) was added to each well and
incubated for 30 min at room temperature. After incubation, the plate was centrifuged for 1 min
at low rpm. The minimum full hemagglutination inhibition for LecA was found to be 1.2 µg/mL.
Further analysis of inhibition of LecA-induced hemagglutination was performed with LecA at 4xHU
(4.8 µg/mL). Briefly, 25 µL of each nanoparticle formulation was subjected to a two-fold serial dilution
in Tris buffer and LecA was added to a final concentration of 4xHU. The plate was then incubated
for 2 h at room temperature. After incubation, normalized 5% blood solution (10 µL) was added.
The plate was then incubated for 30 min at room temperature and then centrifuged for 1 min at low
rpm before analysis.
5.5. Crystal Violet Biofilm Inhibition Assay
The effect of inhibitors on static biofilm formation was evaluated using the crystal violet staining
method with P. aeruginosa strain PAO1 [25] following the established procedure [41]. Briefly, overnight
cultures of P. aeruginosa PAO1 were diluted 1:100 into fresh LB media. Compounds were added at
the indicated concentrations in a 96-well microplate before static incubation at 37 ◦C for 24 h. After
incubation, the plates were thoroughly rinsed to remove planktonic cells and the adherent cells were
quantified by staining with crystal violet and measurement of A550. The assay was performed with
five replicates for each compound concentration. After exclusion of the highest and lowest absorbance
readings the remaining triplicate readings were described as means with error bars representing
standard deviations.
5.6. Growth Inhibition Assay
The effect of nanoparticles on bacterial growth was evaluated with P. aeruginosa strain PAO1 [25].
Overnight cultures of P. aeruginosa PAO1 were diluted 1:100 into fresh LB media. Nanoparticle
formulations/compounds were added at the indicated concentrations in a 96-well microplate. The plate
was placed in a Molecular Devices SpectraMax i3x incubating plate reader set at 37 ◦C with shaking.
Measurement of A600 was recorded every 15 min for the duration of the experiment. Readings are
reported as means with error bars representing the standard deviations of triplicate analyses.
5.7. Fluorescent Confocal Microscopy
The effect of inhibitors on static biofilm formation was evaluated by confocal fluorescence
microscopy with P. aeruginosa strain PA14 [25] following the established procedure [42]. Briefly,
overnight cultures of PA14-GFP [23] were diluted 1:100 into the designated media. Compounds were
added at the indicated concentrations in 96-well microplates with optical grade glass bottoms (Corning)
before static incubation at 37 ◦C for 24 h. After incubation, the samples were imaged on a Nikon
Eclipse TI confocal microscope equipped with a 10X lens. Images were acquired from a central point in
each well of the microplate. Each compound concentration was evaluated in duplicate. Image stacks
were analyzed using Comstat2 [43,44].
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